Brígida Dias Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brígida Dias Fernandes has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Clarice Chemello
Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil
6 shared publications - Aline Aparecida Foppa
Universidade Federal de Minas Gerais, Brasil
3 shared publications - Paulo Henrique Ribeiro Fernandes Almeida
Universidade Federal de Minas Gerais
3 shared publications - Alessandra Rezende Mesquita
Laboratory of Teaching and Research in Social Pharmacy (LEPFS), Federal University of Sergipe, São Cristóvão, Sergipe, Brazil
2 shared publications - Ana Carolina Melchiors
Universidade Federal do Paraná
2 shared publications - Ana Rafaela Pires Lira
Universidade Federal de Minas Gerais
2 shared publications
Latest Publications
- Open Access
- 9 November 2025
- Published by Revista Brasileira de Farmacia Hospitalar e Servicos de Saude in Journal of Hospital Pharmacy and Health Services
- Vol. 16 (4) , e1313
A pharmacist-led medication reconciliation and review program in a pediatric ward
Objective: To determine the types of drug discrepancies at different points in the transition of care (admission, transfer, and discharge) and medication errors in hospitalized pediatric patients. Methods: This observational study was conducted from April to August 2019 with pediatric patients admitted to a university hospital in Minas Gerais, Brazil. The patients included were aged between 28 days and 12 years, and their guardians were interviewed within the first 48 hours after admission. Based on medication reconciliation, intentional and unintentional discrepancies were assessed at all transitions of care, and medication review was performed according to the Pharmaceutical Care Network Europe guidelines for identifying medication errors. Data were analyzed using the SPSS software. A descriptive analysis of the outcomes and other variables was performed, presenting the frequency and percentage of qualitative variables, as well as the median of quantitative variables of quantitative variables. Pearson’s chi-square test was performed for association of variables, with a 95% significance level. Results: Sixty-nine patients were included. The majority were male (55.1%; n = 38), with a median age (SD) of 34.09 (3.4) years (variation of 0 to 12). A total of 399 drug discrepancies were identified, with the transfer from the emergency room to hospital care being the interface with the highest rate of undocumented intentional discrepancies (10.0%; p = 0.001). Unintentional discrepancies were more frequent during the transition from home to the emergency room (13.3%; p = 0.001). Regarding medication review, 185 medication errors were identified in 79.7% of patients, 65.3% of which were related to treatment safety. Regarding transitions of care and hospitalization, 40.6% of patients presented unintentional drug discrepancies and medication errors. Conclusion: Integrated medication review with medication reconciliation can be effective in reducing harm, promoting treatment safety, and optimizing patient’s pharmacoterapy.
- 9 November 2025
- Published by Revista Brasileira de Farmacia Hospitalar e Servicos de Saude in Journal of Hospital Pharmacy and Health Services
- Vol. 16 (4) , e1313
Open AccessA pharmacist-led medication reconciliation and review program in a pediatric ward
Objective: To determine the types of drug discrepancies at different points in the transition of care (admission, transfer, and discharge) and medication errors in hospitalized pediatric patients. Methods: This observational study was conducted from April to August 2019 with pediatric patients admitted to a university hospital in Minas Gerais, Brazil. The patients included were aged between 28 days and 12 years, and their guardians were interviewed within the first 48 hours after admission. Based on medication reconciliation, intentional and unintentional discrepancies were assessed at all transitions of care, and medication review was performed according to the Pharmaceutical Care Network Europe guidelines for identifying medication errors. Data were analyzed using the SPSS software. A descriptive analysis of the outcomes and other variables was performed, presenting the frequency and percentage of qualitative variables, as well as the median of quantitative variables of quantitative variables. Pearson’s chi-square test was performed for association of variables, with a 95% significance level. Results: Sixty-nine patients were included. The majority were male (55.1%; n = 38), with a median age (SD) of 34.09 (3.4) years (variation of 0 to 12). A total of 399 drug discrepancies were identified, with the transfer from the emergency room to hospital care being the interface with the highest rate of undocumented intentional discrepancies (10.0%; p = 0.001). Unintentional discrepancies were more frequent during the transition from home to the emergency room (13.3%; p = 0.001). Regarding medication review, 185 medication errors were identified in 79.7% of patients, 65.3% of which were related to treatment safety. Regarding transitions of care and hospitalization, 40.6% of patients presented unintentional drug discrepancies and medication errors. Conclusion: Integrated medication review with medication reconciliation can be effective in reducing harm, promoting treatment safety, and optimizing patient’s pharmacoterapy.
- 6 June 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 21 (10) , 765-783
Improving patient safety culture in hospitals: A scoping review
- 6 June 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 21 (10) , 765-783
Improving patient safety culture in hospitals: A scoping review
- 3 September 2024
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 22 (12) , 2559-2566
Artificial intelligence applied in human health technology assessment: a scoping review protocol
Objective: This scoping review aims to map studies that applied artificial intelligence (AI) tools to perform health technology assessment tasks in human health care. The review also aims to understand specific processes in which the AI tools were applied and to comprehend the technical characteristics of these tools. Introduction: Health technology assessment is a complex, time-consuming, and labor-intensive endeavor. The development of automation techniques using AI has opened up new avenues for accelerating such assessments in human health settings. This could potentially aid health technology assessment researchers and decision-makers to deliver higher quality evidence. Inclusion criteria: This review will consider studies that assess the use of AI tools in any process of health technology assessment in human health. However, publications in which AI is a means of clinical aid, such as diagnostics or surgery will be excluded. Methods: A search for relevant articles will be conducted in databases such as CINAHL (EBSCOhost), Embase (Ovid), MEDLINE (PubMed), Science Direct, Computer and Applied Sciences Complete (EBSCOhost), LILACS, Scopus, and Web of Science Core Collection. A search for gray literature will be conducted in GreyLit.Org, ProQuest Dissertations and Theses, Google Scholar, and the Google search engine. No language filters will be applied. Screening, selection, and data extraction will be performed by 2 independent reviewers. The results will be presented in graphic and tabular format, accompanied by a narrative summary. Review registration: Open Science Framework osf.io/3rm8g
- 3 September 2024
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 22 (12) , 2559-2566
Artificial intelligence applied in human health technology assessment: a scoping review protocol
Objective: This scoping review aims to map studies that applied artificial intelligence (AI) tools to perform health technology assessment tasks in human health care. The review also aims to understand specific processes in which the AI tools were applied and to comprehend the technical characteristics of these tools. Introduction: Health technology assessment is a complex, time-consuming, and labor-intensive endeavor. The development of automation techniques using AI has opened up new avenues for accelerating such assessments in human health settings. This could potentially aid health technology assessment researchers and decision-makers to deliver higher quality evidence. Inclusion criteria: This review will consider studies that assess the use of AI tools in any process of health technology assessment in human health. However, publications in which AI is a means of clinical aid, such as diagnostics or surgery will be excluded. Methods: A search for relevant articles will be conducted in databases such as CINAHL (EBSCOhost), Embase (Ovid), MEDLINE (PubMed), Science Direct, Computer and Applied Sciences Complete (EBSCOhost), LILACS, Scopus, and Web of Science Core Collection. A search for gray literature will be conducted in GreyLit.Org, ProQuest Dissertations and Theses, Google Scholar, and the Google search engine. No language filters will be applied. Screening, selection, and data extraction will be performed by 2 independent reviewers. The results will be presented in graphic and tabular format, accompanied by a narrative summary. Review registration: Open Science Framework osf.io/3rm8g
- Open Access
- 7 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0302860
Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis
Background: Onasemnogene abeparvovec has been approved for the treatment of spinal muscular atrophy 5q type 1 in several countries, which calls for an independent assessment of the evidence regarding efficacy and safety. Objective: Conduct a meta-analysis to assess the efficacy and safety of onasemnogene abeparvovec in patients diagnosed with SMA type 1, based on the available evidence. Methods: This article results from searches conducted on databases up to November 2022. Outcomes of interest were global survival and event-free survival, improvement in motor function and treatment-related adverse events. Risk of bias assessment and certainty of evidence were performed for each outcome. Proportional meta-analysis models were performed when applicable. Results: Four reports of three open-label, non-comparative clinical trials covering 67 patients were included. Meta-analyses of data available in a 12-month follow-up estimate a global survival of 97.56% (95%CI: 92.55 to 99.86, I2 = 0%, n = 67), an event-free survival of 96.5% (95%CI: 90.76 to 99.54, I2 = 32%, n = 66) and a CHOP-INTEND score ≥ 40 points proportion of 87.28% (95%CI: 69.81 to 97.83, I2 = 69%, n = 67). Proportion of 52.64% (95%CI: 27.11 to 77.45, I2 = 78%, n = 67) of treatment-related adverse events was estimated. Conclusion: The results indicate a potential change in the natural history of type 1 SMA, but the methodological limitations of the studies make the real extent of the technology’s long-term benefits uncertain.
- 7 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0302860
Open AccessEfficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis
Background: Onasemnogene abeparvovec has been approved for the treatment of spinal muscular atrophy 5q type 1 in several countries, which calls for an independent assessment of the evidence regarding efficacy and safety. Objective: Conduct a meta-analysis to assess the efficacy and safety of onasemnogene abeparvovec in patients diagnosed with SMA type 1, based on the available evidence. Methods: This article results from searches conducted on databases up to November 2022. Outcomes of interest were global survival and event-free survival, improvement in motor function and treatment-related adverse events. Risk of bias assessment and certainty of evidence were performed for each outcome. Proportional meta-analysis models were performed when applicable. Results: Four reports of three open-label, non-comparative clinical trials covering 67 patients were included. Meta-analyses of data available in a 12-month follow-up estimate a global survival of 97.56% (95%CI: 92.55 to 99.86, I2 = 0%, n = 67), an event-free survival of 96.5% (95%CI: 90.76 to 99.54, I2 = 32%, n = 66) and a CHOP-INTEND score ≥ 40 points proportion of 87.28% (95%CI: 69.81 to 97.83, I2 = 69%, n = 67). Proportion of 52.64% (95%CI: 27.11 to 77.45, I2 = 78%, n = 67) of treatment-related adverse events was estimated. Conclusion: The results indicate a potential change in the natural history of type 1 SMA, but the methodological limitations of the studies make the real extent of the technology’s long-term benefits uncertain.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Interface - Comunicação, Saúde, Educação
- Vol. 28, e230092
Ensino experiencial na farmácia universitária: um estudo de perspectiva etnográfica na educação
O objetivo deste estudo foi refletir sobre o desafio da formação de identidade profissional do farmacêutico clínico em um contexto de currículo não integrado e em um ambiente tradicional e especializado. Desenvolveu-se uma pesquisa qualitativa orientada pelos pressupostos da perspectiva etnográfica na educação, empregando-se múltiplos métodos de coleta de dados entre abril e julho de 2019. O cenário de ensino experiencial foi uma Farmácia Universitária da região Sul do Brasil. Por meio de uma descrição densa e com uso da reflexividade teórica e intertextual, é apresentada uma narrativa utilizando a voz dos participantes como âncora para dar visibilidade ao processo vivenciado. A ausência de um padrão para o cuidado na profissão farmacêutica, o currículo tradicional e a desarticulação entre teoria e prática constituem desafios para os estudantes de Farmácia legitimarem a prática profissional farmacêutica centrada no usuário.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Interface - Comunicação, Saúde, Educação
- Vol. 28, e230092
Open AccessEnsino experiencial na farmácia universitária: um estudo de perspectiva etnográfica na educação
O objetivo deste estudo foi refletir sobre o desafio da formação de identidade profissional do farmacêutico clínico em um contexto de currículo não integrado e em um ambiente tradicional e especializado. Desenvolveu-se uma pesquisa qualitativa orientada pelos pressupostos da perspectiva etnográfica na educação, empregando-se múltiplos métodos de coleta de dados entre abril e julho de 2019. O cenário de ensino experiencial foi uma Farmácia Universitária da região Sul do Brasil. Por meio de uma descrição densa e com uso da reflexividade teórica e intertextual, é apresentada uma narrativa utilizando a voz dos participantes como âncora para dar visibilidade ao processo vivenciado. A ausência de um padrão para o cuidado na profissão farmacêutica, o currículo tradicional e a desarticulação entre teoria e prática constituem desafios para os estudantes de Farmácia legitimarem a prática profissional farmacêutica centrada no usuário.
- Open Access
- 21 June 2023
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 7 (4)
Comunicação breve: Revisão Sistemática da eficácia e segurança do onasemnogeno abeparvoveque para tratamento de pacientes com Atrofia Muscular Espinhal Tipo 1
Objetivo: Foram avaliadas evidências de eficácia e segurança do onasemnogeno abeparvoveque no tratamento da atrofia muscular espinhal tipo 1. Método: Foi conduzida uma revisão sistemática da literatura, conforme protocolo aprovado previamente. Resultados: Três estudos foram selecionados, START, STR1VE e STR1VE-EU, com alto risco de viés e certeza da evidência de muito baixa qualidade. Foram reportadas sobrevida global de 91 a 100%, sobrevida livre de ventilação mecânica de 39 a 82% e eventos adversos relacionados ao tratamento em 25 a 73% dos pacientes. Conclusões: É incerto o real benefício do onasemnogeno abeparvoveque e desafiadora a tomada de decisão para sua incorporação no SUS.
- 21 June 2023
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 7 (4)
Open AccessComunicação breve: Revisão Sistemática da eficácia e segurança do onasemnogeno abeparvoveque para tratamento de pacientes com Atrofia Muscular Espinhal Tipo 1
Objetivo: Foram avaliadas evidências de eficácia e segurança do onasemnogeno abeparvoveque no tratamento da atrofia muscular espinhal tipo 1. Método: Foi conduzida uma revisão sistemática da literatura, conforme protocolo aprovado previamente. Resultados: Três estudos foram selecionados, START, STR1VE e STR1VE-EU, com alto risco de viés e certeza da evidência de muito baixa qualidade. Foram reportadas sobrevida global de 91 a 100%, sobrevida livre de ventilação mecânica de 39 a 82% e eventos adversos relacionados ao tratamento em 25 a 73% dos pacientes. Conclusões: É incerto o real benefício do onasemnogeno abeparvoveque e desafiadora a tomada de decisão para sua incorporação no SUS.
- Open Access
- 25 April 2023
- Published by Editora Unijui in Revista Contexto & Saúde
- Vol. 23 (47) , e13327
Reconciliação de medicamentos e potencial de dano dos erros de medicação na admissão hospitalar de pacientes pediátricos
Objetivo: Descrever o potencial impacto clínico de discrepâncias medicamentosas não intencionais a que pacientes pediátricos estão expostos na admissão hospitalar. Métodos: Estudo observacional descritivo, conduzido na unidade de pronto atendimento pediátrica de um hospital universitário, no período de abril a agosto de 2019. Foram incluídos pacientes hospitalizados por pelo menos 48 horas, com idades entre 28 dias e 12 anos. Foi realizada uma entrevista com as crianças e os seus acompanhantes e suas prescrições (domiciliares e hospitalares) foram reconciliadas. As discrepâncias encontradas foram classificadas em intencional, intencional não documentada e não intencional. A análise descritiva foi realizada para caracterizar o perfil da amostra, as discrepâncias não intencionais e o potencial de causar dano em razão dos erros envolvidos. O potencial de causar dano dos erros de medicação foi avaliado por um painel de 11 farmacêuticos especialistas. Resultados: Foram incluídos 69 pacientes, com mediana de 3 anos de idade, 55% do sexo masculino. Foram reconciliados 252 medicamentos, dos quais 53 (21%) estavam envolvidos em erro de medicação. Quase metade dos pacientes 28 (41%) teve pelo menos um erro de medicação na admissão hospitalar, com o mais prevalente sendo a omissão 24 (45%). Caso esses erros não tivessem sido detectados, 31 (58%) deles poderiam ter causado danos nocivos aos pacientes (Nível 3) e 18 (34%) exigiram um maior monitoramento ou intervenção para evitar danos (Nível 2). Conclusão: O estudo demonstra alta frequência de discrepâncias não intencionais que foram classificadas como dano potencial em pacientes pediátricos.
- 25 April 2023
- Published by Editora Unijui in Revista Contexto & Saúde
- Vol. 23 (47) , e13327
Open AccessReconciliação de medicamentos e potencial de dano dos erros de medicação na admissão hospitalar de pacientes pediátricos
Objetivo: Descrever o potencial impacto clínico de discrepâncias medicamentosas não intencionais a que pacientes pediátricos estão expostos na admissão hospitalar. Métodos: Estudo observacional descritivo, conduzido na unidade de pronto atendimento pediátrica de um hospital universitário, no período de abril a agosto de 2019. Foram incluídos pacientes hospitalizados por pelo menos 48 horas, com idades entre 28 dias e 12 anos. Foi realizada uma entrevista com as crianças e os seus acompanhantes e suas prescrições (domiciliares e hospitalares) foram reconciliadas. As discrepâncias encontradas foram classificadas em intencional, intencional não documentada e não intencional. A análise descritiva foi realizada para caracterizar o perfil da amostra, as discrepâncias não intencionais e o potencial de causar dano em razão dos erros envolvidos. O potencial de causar dano dos erros de medicação foi avaliado por um painel de 11 farmacêuticos especialistas. Resultados: Foram incluídos 69 pacientes, com mediana de 3 anos de idade, 55% do sexo masculino. Foram reconciliados 252 medicamentos, dos quais 53 (21%) estavam envolvidos em erro de medicação. Quase metade dos pacientes 28 (41%) teve pelo menos um erro de medicação na admissão hospitalar, com o mais prevalente sendo a omissão 24 (45%). Caso esses erros não tivessem sido detectados, 31 (58%) deles poderiam ter causado danos nocivos aos pacientes (Nível 3) e 18 (34%) exigiram um maior monitoramento ou intervenção para evitar danos (Nível 2). Conclusão: O estudo demonstra alta frequência de discrepâncias não intencionais que foram classificadas como dano potencial em pacientes pediátricos.
- 1 November 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (2) , 374-382
Factors Associated With PIM use in the Frail Elderly: A Cross-sectional Study
Background: The use of potentially inappropriate medications (PIM) by the elderly is commonly studied, but studies evaluating the use of PIM by frail elderly covered by prepaid health plans are still lacking. Objective: To identify the prevalence of use and the factors associated with the use of PIM by the elderly patients with high and moderate risk of clinical-functional vulnerability, according to the Beers criteria 2019. Methods: A cross-sectional study was developed with elderly people from a private health plan in Vitória-ES, Brazil. Socioeconomic, demographic and clinical data were collected through a digital platform and a structured questionnaire through an interview, from October 2018 to June 2019. The association between the use of PIM and independent variables was verified by univariate logistic regression with their respective confidence intervals (CI) 95%. The Multiple Model included the variables with P ≤ .20. Results: 332 elderly patients were interviewed (mean age 81.5 years, gender 237 female, 95 male). A 65% prevalence of PIM use was identified. In the multiple logistic regression model, the variables associated with the use of PIM were self-medication ( P = .004), high risk of clinical-functional vulnerability ( P = .022), use of psychotropic medications ( P = .000001), musculoskeletal medications ( P = .04) and alimentary tract medications ( P = .03). Physical exercises were considered a protection factor ( P = .02). Conclusion: The high prevalence of PIM use indicates the need for improvement in elderly private health care, to increase pharmacotherapy safety for this population.
- 1 November 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (2) , 374-382
Factors Associated With PIM use in the Frail Elderly: A Cross-sectional Study
Background: The use of potentially inappropriate medications (PIM) by the elderly is commonly studied, but studies evaluating the use of PIM by frail elderly covered by prepaid health plans are still lacking. Objective: To identify the prevalence of use and the factors associated with the use of PIM by the elderly patients with high and moderate risk of clinical-functional vulnerability, according to the Beers criteria 2019. Methods: A cross-sectional study was developed with elderly people from a private health plan in Vitória-ES, Brazil. Socioeconomic, demographic and clinical data were collected through a digital platform and a structured questionnaire through an interview, from October 2018 to June 2019. The association between the use of PIM and independent variables was verified by univariate logistic regression with their respective confidence intervals (CI) 95%. The Multiple Model included the variables with P ≤ .20. Results: 332 elderly patients were interviewed (mean age 81.5 years, gender 237 female, 95 male). A 65% prevalence of PIM use was identified. In the multiple logistic regression model, the variables associated with the use of PIM were self-medication ( P = .004), high risk of clinical-functional vulnerability ( P = .022), use of psychotropic medications ( P = .000001), musculoskeletal medications ( P = .04) and alimentary tract medications ( P = .03). Physical exercises were considered a protection factor ( P = .02). Conclusion: The high prevalence of PIM use indicates the need for improvement in elderly private health care, to increase pharmacotherapy safety for this population.
- 1 August 2022
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 18 (8) , 3263-3271
Application and utility of geographic information systems in pharmacy specific health research: A scoping review
- 1 August 2022
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 18 (8) , 3263-3271
Application and utility of geographic information systems in pharmacy specific health research: A scoping review